Dr Zuzana Walker

Photo

Personal Profile

Name: Zuzana Walker Email: z.walker@ucl.ac.uk
Title: Dr Tel: 01279 827893
Department: Division of Psychiatry Fax:
Position: Reader in Psychiatry of the Elderly Address: Charles Bell House, 67-73 Riding House Street, London, W1W 7WY
Research Domain: Ageing, Biomedical Imaging (Frontier Disciplines), Neuroscience, Populations & Lifelong Health Web Page: Personal Web Page

Profile

Research Description

I have been actively involved in research in dementia since 1993. My main areas of research are Dementia with Lewy bodies (DLB), functional and molecular neuroimaging in subjective and  mild cognitive impairment, post-mortem validation of clinical and imaging findings and new treatments in dementia. I have published a number of key papers on neuroimaging of the dopamine transporter in DLB & Parkinson’s disease. I am the lead consultant in the West Essex Neurocognitive Clinic which is well established, has an extensive database and is the focus for a number of research projects and treatment trials. The clinic is linked to the Brain donation program in Essex, UK.


Research Activities

Ageing and mental health in adults with intellectual disabilities and other neurodevelopmental conditions

Piloting a complex intervention involving physical exercise, cognitive training and socialising to delay the onset of dementia in mild cognitive impairment. (ThinkingFit)

Education Description

UCL Collaborators

Prof Gill Livingston; Dr Thomas Dannhauser; Dr Andre Strydom; Prof Michael King

External Collaborators

Dr Fernando Sepulveda; Prof Ben Fletcher

Publications

    2014

    • Livingston G, Barber J, Rapaport P, Knapp M, Griffin M, King D, Romeo R, Livingston D, Mummery C, Walker Z, Hoe J, Cooper C (2014). Long-term clinical and cost-effectiveness of psychological intervention for family carers of people with dementia: a single-blind, randomised, controlled trial. The Lancet Psychiatry, 1(7), 539 - 548. doi:10.1016/S2215-0366(14)00073-X
    • Dean K, Jenkinson C, Wilcock G, Walker Z (2014). The development and validation of a patient-reported quality of life measure for people with mild cognitive impairment.. Int Psychogeriatr, 26(3), 487 - 497. doi:10.1017/S1041610213002251
    • Sheehan R, Sinai A, Bass N, Blatchford P, Bohnen I, Bonell S, Courtenay K, Hassiotis A, Markar T, McCarthy J, Mukherji K, Naeem A, Paschos D, Perez-Achiaga N, Sharma V, Thomas D, Walker Z, Strydom A (2014). Dementia diagnostic criteria in Down syndrome.. Int J Geriatr Psychiatry, , - . doi:10.1002/gps.4228
    • Livingston G, Barber J, Rapaport P, Knapp M, Griffin M, Romeo R, King D, Livingston D, Lewis-Holmes E, Mummery C, Walker Z, Hoe J, Cooper C (2014). START (STrAtegies for RelaTives) study: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manual-based coping strategy programme in promoting the mental health of carers of people with dementia.. Health Technol Assess, 18(61), 1 - 242. doi:10.3310/hta18610
    • O'Brien JT, Oertel WH, McKeith IG, Grosset DG, Walker Z, Tatsch K, Tolosa E, Sherwin PF, Grachev ID (2014). Diagnostic performance of ioflupane I123 injection (DaTSCAN (TM)) in patients with movement disorders and dementia.
    • Walker Z, Thomas A, Inglis F, Tabet N, Rainer M, Banica M, Grachev I, Moreno E, Padovani A, Grp DDLBS (2014). Prevalence of DLB features in possible dementia with Lewy bodies and its relationship to changes in dementia diagnostic category after dopamine transporter imaging using DaTSCAN (TM).
    • Walker Z, Ducksbury R, Rodda J, Nagaraj C, Whitfield T, Suresh K, Stevens T, Saez-Fonseca A (2014). Factors that predict cognitive decline in patients with subjective cognitive impairment.
    • O'Brien JT, Oertel WH, McKeith IG, Grosset DG, Walker Z, Tatsch K, Tolosa E, Sherwin PF, Grachev ID (2014). Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials.. BMJ Open, 4(7), e005122 - . doi:10.1136/bmjopen-2014-005122
    • Azam B, Whitfield TJ, Radford D, Dontham SG, Stevens T, Dannhauser T, Walker Z (2014). Trends in referred patient profiles in a memory clinic over 20 years.. Dementia (London), , - . doi:10.1177/1471301214539691
    • Zis P, McHugh P, McQuillin A, Praticò D, Dickinson M, Shende S, Walker Z, Strydom A (2014). Memory Decline in Down Syndrome and Its Relationship to iPF2alpha, a Urinary Marker of Oxidative Stress.. PLoS One, 9(6), e97709 - . doi:10.1371/journal.pone.0097709
    • Stanley K, Walker Z (2014). Do patients with young onset Alzheimer's disease deteriorate faster than those with late onset Alzheimer's disease? A review of the literature.. Int Psychogeriatr, , 1 - 9. doi:10.1017/S1041610214001173
    • Grosset DG, Tatsch K, Oertel WH, Tolosa E, Bajaj N, Kupsch A, O'Brien JT, Seibyl J, Walker Z, Sherwin P, Chen C, Grachev ID (2014). Safety Analysis of 10 Clinical Trials and for 13 Years After First Approval of Ioflupane 123I Injection (DaTscan).. J Nucl Med, , - . doi:10.2967/jnumed.114.138032
    • Dannhauser TM, Cleverley M, Whitfield TJ, Fletcher BC, Stevens T, Walker Z (2014). A complex multimodal activity intervention to reduce the risk of dementia in mild cognitive impairment-ThinkingFit: pilot and feasibility study for a randomized controlled trial.. BMC Psychiatry, 14(1), 129 - . doi:10.1186/1471-244X-14-129
    • Seibyl JP, Kupsch A, Booij J, Grosset DG, Costa DC, Hauser RA, Darcourt J, Bajaj N, Walker Z, Marek K, McKeith I, O'Brien JT, Tatsch K, Tolosa E, Dierckx RA, Grachev ID (2014). Individual-Reader Diagnostic Performance and Between-Reader Agreement in Assessment of Subjects with Parkinsonian Syndrome or Dementia Using 123I-Ioflupane Injection (DaTscan) Imaging.. J Nucl Med, , - . doi:10.2967/jnumed.114.140228
    • Dean K, Jenkinson C, Wilcock G, Walker Z (2014). Exploring the experiences of people with mild cognitive impairment and their caregivers with particular reference to healthcare - a qualitative study.. Int Psychogeriatr, 26(3), 475 - 485. doi:10.1017/S104161021300207X
    • Walker Z, Moreno E, Thomas A, Inglis F, Tabet N, Rainer M, Pizzolato G, Padovani A, the DaTSCAN DLB Phase 4 Study Group (2014). Clinical usefulness of dopamine transporter SPECT imaging with 123I-FP-CIT in patients with possible dementia with Lewy bodies: randomised study.. Br J Psychiatry, , - . doi:10.1192/bjp.bp.114.148643

    2013

    • Knapp M, King D, Romeo R, Schehl B, Barber J, Griffin M, Rapaport P, Livingston D, Mummery C, Walker Z, Hoe J, Sampson EL, Cooper C, Livingston G (2013). Cost effectiveness of a manual based coping strategy programme in promoting the mental health of family carers of people with dementia (the START (STrAtegies for RelaTives) study): a pragmatic randomised controlled trial.. BMJ, 347, f6342 - .
    • Livingston G, Barber J, Rapaport P, Knapp M, Griffin M, King D, Livingston D, Mummery C, Walker Z, Hoe J, Sampson EL, Cooper C (2013). Clinical effectiveness of a manual based coping strategy programme (START, STrAtegies for RelaTives) in promoting the mental health of carers of family members with dementia: pragmatic randomised controlled trial.. BMJ, 347, f6276 - .
    • Rodda J, Gandhi SD, Mukadam N, Walker Z (2013). Attitudes of UK psychiatrists to the diagnosis of MCI in clinical practice.. Int Psychogeriatr, 25(2), 286 - 291. doi:10.1017/S1041610212001500
    • Edison P, Ahmed I, Fan Z, Hinz R, Gelosa G, Chaudhuri KR, Walker Z, Turkheimer FE, Brooks DJ (2013). Microglia, Amyloid, and Glucose Metabolism in Parkinson's Disease with and without Dementia. NEUROPSYCHOPHARMACOLOGY, 38(6), 938 - 949. doi:10.1038/npp.2012.255
    • Lomena F, Oliver G, Barber C, Moreno E, Volterrani D, Daumal J, Flores D, Serena A, Walker Z, Grp DDLBS (2013). Predictors of dopamine transporter DaTSCAN (TM) ( Ioflupane I-123) SPECT imaging results in subjects with possible Dementia with Lewy Bodies.
    • Paghera B, Prosser J, Leitha T, Howe K, Moreno E, Dore F, Dizdarevic S, Stabell U, Walker Z, Grp DDLBS (2013). Changes in Dementia Diagnostic Category and Diagnostic Confidence following dopamine transporter SPECT imaging with DaTSCAN (TM) (Ioflupane I-123) in Subjects with an Uncertain Diagnosis of Dementia with Lewy Bodies (possible DLB).
    • Dean K, Walker Z, Churchman D, Wilcock G, Jenkinson C (2013). THE DEVELOPMENT AND VALIDATION OF A QUALITY OF LIFE MEASURE FOR PEOPLE WITH MILD COGNITIVE IMPAIRMENT (THE MCQ). VALUE IN HEALTH, 16(7), A550 - A550.

    2012

    • Walker Z, Gamez J, Sadowsky C, Singh U, Sabbagh M, Rinne J, Leinonen V, Wong D, Wolk D, Buckley C, Sherwin P, Smith A, Brooks D, Farrar G, Grachev ID (2012). A strong concordance between [F-18]flutemetamol PET and amyloid-beta pathology demonstrated in brain autopsy and in-vivo cortical biopsy trials.
    • Zis P, Dickinson M, Shende S, Walker Z, Strydom A (2012). Superoxide dismutase (SOD1) functioning as a predictor of memory decline in Down syndrome (DS).
    • Morgan S, Kemp P, Booij J, Costa DC, Padayachee S, Lee L, Barber C, Carter J, Walker Z (2012). Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 83(11), 1063 - 1070. doi:10.1136/jnnp-2012-302577
    • Walker Z, Cummings JL (2012). [123I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane single-photon emission computed tomography brain imaging in the diagnosis of dementia with Lewy bodies.. Alzheimers Dement, 8(1), 74 - 83. doi:10.1016/j.jalz.2011.08.003
    • Warr L, Walker Z (2012). Identification of biomarkers in Lewy-body disorders.. Q J Nucl Med Mol Imaging, 56(1), 39 - 54.
    • Walker Z, McKeith I, Rodda J, Qassem T, Tatsch K, Booij J, Darcourt J, O'Brien J (2012). Comparison of cognitive decline between dementia with Lewy bodies and Alzheimer's disease: a cohort study.. BMJ Open, 2, e000380 - . doi:10.1136/bmjopen-2011-000380
    • Zis P, Dickinson M, Shende S, Walker Z, Strydom A (2012). Oxidative stress and memory decline in adults with Down syndrome: longitudinal study.. J Alzheimers Dis, 31(2), 277 - 283. doi:10.3233/JAD-2012-120073

    2011

    • Rodda J, Dannhauser T, Cutinha DJ, Shergill SS, Walker Z (2011). Subjective cognitive impairment: functional MRI during a divided attention task.. Eur Psychiatry, 26(7), 457 - 462. doi:10.1016/j.eurpsy.2010.07.003
    • Sabri O, Gertz H, Ischihara K, Tateno A, Drzezga A, Grimmer T, Senda M, Yamamoto Y, Hiemeyer F, McKeith I, O'Brien J, Walker Z, Reininger C, Seibyl J, Barthel H (2011). Global phase 2b efficacy and safety trial of florbetaben for beta-amyloid brain positron emission tomography in Alzheimer's disease. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 38, S121 - S121.
    • Rodda J, Walker Z, Carter J (2011). Depression in older adults.. BMJ, 343, d5219 - .
    • Walker Z, Rodda J (2011). Dopaminergic imaging: clinical utility now and in the future.. Int Psychogeriatr, 23(Supplement 2), S32 - S40. doi:10.1017/S1041610211000883
    • Lamar M, Dannhauser TM, Walker Z, Rodda JE, Cutinha DJ, Shergill SS (2011). Memory Complaints with and without Memory Impairment: The Impact of Leukoaraiosis on Cognition. JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY, 17(6), 1104 - 1112. doi:10.1017/S1355617711001123

    2010

    • Cooper C, Blanchard M, Selwood A, Walker Z, Livingston G (2010). Family carers' distress and abusive behaviour: longitudinal study.. Br J Psychiatry, 196(6), 480 - 485. doi:10.1192/bjp.bp.109.071811
    • Darcourt J, Booij J, Tatsch K, Varrone A, Borght TV, Kapucu OL, Nagren K, Nobili F, Walker Z, Van Laere K (2010). EANM procedure guidelines for brain neurotransmission SPECT using I-123-labelled dopamine transporter ligands, version 2. EUR J NUCL MED MOL I, 37(2), 443 - 450. doi:10.1007/s00259-009-1267-x
    • Rodda J, Okello A, Edison P, Dannhauser T, Brooks D, Walker Z (2010). C-PIB PET in Subjective Cognitive Impairment. European Psychiatry, , - .
    • Cooper C, Selwood A, Blanchard M, Walker Z, Blizard R, Livingston G (2010). The determinants of family carer’s abusive behaviour to people with dementia: results of the CARD study. Journal of Affective disorders, 121(1-2), 136 - 142.

    2009

    • Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Nagren K, Bullock R, Walker Z, Kennedy A, Fox NC, Rossor MN, Rinne JO, Brooks DJ (2009). Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.. Neurology, 73(10), 754 - 760. doi:10.1212/WNL.0b013e3181b23564
    • Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, Leroi I, Pozo-Rodriguez F, Minthon L, Londos E (2009). Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. LANCET NEUROL, 8(7), 613 - 618. doi:10.1016/S1474-4422(09)70146-2
    • Paradise M, Walker Z, Cooper C, Blizard R, Regan C, Katona C, Livingston G (2009). Prediction of survival in Alzheimer's disease--the LASER-AD longitudinal study.. Int J Geriatr Psychiatry, 24(7), 739 - 747. doi:10.1002/gps.2190
    • Rodda J, Walker Z (2009). Ten years of cholinesterase inhibitors. INT J GERIATR PSYCH, 24(5), 437 - 442. doi:10.1002/gps.2165
    • Cooper C, Selwood A, Blanchard M, Walker Z, Blizard R, Livingston G (2009). Abuse of people with dementia by family carers: representative cross sectional survey.. BMJ, 338, b155 - .
    • Saez Fonseca JA, Lee L, Walker Z (2009). Long-term outcome of depressive pseudodementia in the elderly.
    • Rodda J, Dannhauser T, Cutinha D, Okello A, Shergill S, Brooks D, Walker Z (2009). SUBJECTIVE COGNITIVE IMPAIRMENT: FUNCTIONAL MRI DURING DIVIDED ATTENTION AND MEASUREMENT OF AMYLOID LOAD USING C-11-PIB PET. EUROPEAN PSYCHIATRY, 24, - .
    • Rodda JE, Dannhauser TM, Cutinha DJ, Shergill SS, Walker Z (2009). Subjective cognitive impairment: increased prefrontal cortex activation compared to controls during an encoding task.. Int J Geriatr Psychiatry, 24(8), 865 - 874. doi:10.1002/gps.2207
    • Strydom A, Dickinson MJ, Shende S, Pratico D, Walker Z (2009). Oxidative stress and cognitive ability in adults with Down syndrome. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 33(1), 76 - 80. doi:10.1016/j.pnpbp.2008.10.006
    • Rodda J, Morgan S, Walker Z (2009). Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.. Int Psychogeriatr, 21(5), 813 - 824. doi:10.1017/S1041610209990354
    • O'Brien JT, McKeith IG, Walker Z, Tatsch K, Booij J, Darcourt J, Marquardt M, Reininger C (2009). Diagnostic accuracy of I-123-FP-CIT SPECT in possible dementia with Lewy bodies. BRIT J PSYCHIAT, 194(1), 34 - 39. doi:10.1192/bjp.bp.108.052050
    • Okello A, Edison P, Archer HA, Turkheimer FE, Kennedy J, Bullock R, Walker Z, Kennedy A, Fox N, Rossor M, Brooks DJ (2009). Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology, 72(1), 56 - 62. doi:10.1212/01.wnl.0000338622.27876.0d

    2008

    • Okello A, Edison P, Archer H, Walker Z, Fox N, Kennedy A, Rossor M, Brooks DJ (2008). In vivo imaging of amyloid deposition and neuroinflammation in mild cognitive impairment with 11C-PIB and 11C-PK11195 pet.
    • Rodda J, Boyce N, Walker Z (2008). The Handbook of Old Age Psychiatry.
    • Boyce N, Walker Z (2008). Late Onset and Very Late Onset Schizophrenia-Like psychosis. In (Ed.), Psychiatry (pp. 463 - 466). : .
    • Suresh K, Smalley D, Walker Z (2008). 10-minute consultation: Memory problems in an older person. BMJ (Clinical Research Ed.), 337, a1170 - .
    • Dannhauser TM, Shergill SS, Stevens T, Lee L, Seal M, Walker RW, Walker Z (2008). An fMRI study of verbal episodic memory encoding in amnestic mild cognitive impairment.. Cortex, 44(7), 869 - 880. doi:10.1016/j.cortex.2007.04.005

    2007

    • Walker Z, Jaros E, Walker RW, Lee L, Costa DC, Livingston G, Ince PG, Perry R, McKeith I, Katona CL (2007). Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy.. J Neurol Neurosurg Psychiatry, 78(11), 1176 - 1181. doi:10.1136/jnnp.2006.110122
    • McKeith I, O'Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, Padovani A, Giubbini R, Bonuccelli U, Volterrani D, Holmes C, Kemp P, Tabet N, Meyer I, Reininger C, DLB Study Grp (2007). Sensitivity and specificity of dopamine transporter imaging with I-123-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. LANCET NEUROL, 6(4), 305 - 313. doi:10.1016/S1474-4422(07)70057-1
    • Ahmed I, Edison P, Quinn NQ, Walker Z, Brooks DJ (2007). Amyloid deposition and glucose metabolism in Parkinson's disease dementia (PDD): An [C-11]PIB and [F-18]FDG PET study.
    • Saez Fonseca JA, Cutinha D, Shanker KK, Walker Z (2007). Six years experience with acetylcholinesterase inhibitors in a clinical setting.
    • Walker Z (2007). Dementia with Lewy bodies: A comparison of clinical diagnosis, DaTSCAN imaging and neuropathological diagnosis.
    • Devine ME, Saez Fonseca JA, Walker RWH, Sikdar T, Stevens T, Walker Z (2007). Effect of cerebal white matter changes on clinical response to cholinesterase inhibitors in dementia.
    • Saez-Fonseca JA, Lee L, Walker Z (2007). Long-term outcome of depressive pseudodementia in the elderly. Journal of Affective Disorders, 101(1-3), 123 - 129.
    • Devine ME, Fonseca JA, Walker RW, Sikdar T, Stevens T, Walker Z (2007). Cerebral white matter changes and rate of progression of dementia during cholinesterase inhibitor treatment: a retrospective cohort study. International Journal of Geriatric Psychiatry, 22(11), 1120 - 1126.

    2006

    • Regan C, Katona C, Walker Z, Donovan J, Hooper J, Livingston G (2006). Relationship of vascular risk to the progression of Alzheimer disease.. Neurology, 67(8), 1357 - 1362. doi:10.1212/01.wnl.0000240129.46080.53
    • Walker Z, Costa DC, Walker RWH, Lee L, Livingston G, Jaros E, Perry R, McKeith I, Katona CLE (2006). Comparison of clinical, FP-CIT spet imaging, and autopsy diagnosis of DLB.
    • Walker Z (2006). Progression of cognitive impairment and duration of illness. In O'Brien J, McKeith I, Ames D, Chiu E (Ed.), Dementia with Lewy bodies (pp. 141 - 147). : Taylor & Francis.

    2005

    • Dannhauser TM, Walker Z, Stevens T, Lee L, Seal M, Shergill SS (2005). The functional anatomy of divided attention in amnestic mild cognitive impairment. Brain, 128(6), 1418 - 1427. doi:10.1093/brain/awh413
    • Regan C, Katona C, Walker Z, Livingston G (2005). Relationship of exercise and other risk factors to depression in Alzheimer's disease. The LASER-AD study. International Journal of Geriatric Psychiatry, 20(3), 261 - 268.
    • Qazi A, Richardson B, Simmons P, Mullan E, Walker Z, Katona C, Orrell M (2005). The Mini-SIB: a short scale for measuring cognitive function in severe dementia. International Journal of Geriatric Psychiatry, 20(10), 1001 - 1002.
    • Tabet N, Mantle D, Walker Z, Orrell M (2005). Higher fat and carbohydrate intake in dementia patients is associated with increased blood glutathione peroxidase activity. International Psychogeriatrics, 17(1), 91 - 98. doi:10.1017/S1041610205001006
    • Walker Z, Costa DC, Walker RWH (2005). Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium.
    • Dannhauser TM, Shergill S, Walker Z, Seal M, Stevens T, Lee L (2005). Divided attention in amnestic mild cognitive impairment (AMCI).
    • Walker Z, Walker RW (2005). Imaging in neurodegenerative disorders: recent studies. Current Opinion in Psychiatry, 18(6), 640 - 646.

    2004

    • Stevens T, Livingston G, Kitchen G, Manela M, Walker Z, Katona C (2004). The community prevalence of frontal lobe dementias.
    • Strydom A, Hassiotis A, Walker Z (2004). Magnetic resonance imaging in people with Down's Syndrome and Alzheimer's disease. Journal of Intellectual Disability Research, 48(8), 769 - 770. doi:10.1111/j.1365-2788.2003.00571.x
    • Walker Z, Costa D, Walker RWH, Lee L, Livingston G, Jaros E, Perry R, McKeith I, Katona C (2004). Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology, 69(9), 1568 - 1572.

    2003

    • Serra-Mestres J, Ring HA, Costa DC, Gacinovic S, Walker Z, Lees A, Robertson MM, Trimble MR (2003). Dopamine transporter binding in Gilles de la Tourette syndrome: a [123I]FP-CIT-SPECT study. Acta Psychiatrica Scandinavica, 109(2), 140 - 146. doi:10.1111/j.0001-690X.2004.00214.x
    • Costa DC, Walker Z, Walker RWH, Fontes FRG (2003). Dementia with Lewy bodies versus Alzheimer's disease: Role of dopamine transporter imaging. MOVEMENT DISORD, 18, S34 - S38. doi:10.1002/mds.10576
    • Hassiotis A, Strydom A, Allen K, Walker Z (2003). A memory clinic for older people with intellectual disabilities. Aging and Mental Health, 7(6), pp.418 - 423. doi:10.1080/13607860310001594664
    • Fahy M, Wald C, Walker Z, Livingston G (2003). Secrets and lies: the dilemma of disclosing the diagnosis to an adult with dementia. Age and Ageing, 32, 439 - 441.
    • Carbonell J, Allen R, Kalsi G, McQuillin A, Livingston G, Katona C, Walker Z, Katz A, Rands G, Stevens T, Crossan I, Curtis D, Gurling H (2003). Variation in the DCP1 gene, encoding the angiotensin converting enzyme ACE, is not associated with increased susceptibility to Alzheimer's disease. Psychiatr Genet, 13, 47 - 50. doi:10.1097/01.ypg.0000054711.85338.5c
    • Wald C, Fahy M, Livingston G, Walker Z (2003). What to tell dementia caregivers - the rule of threes. International Journal of Geriatric Psychiatry, 18, 313 - 317.
    • Tabet N, Walker Z, Mantle D, Costa DC, Orrell M (2003). In vivo dopamine pre-synaptic receptors and antioxidant activities in patients with Alzheimer's disease, dementia with Lewy bodies and controls: a preliminary report.. Dementia and Geriatric Cognitive Disorders, 16(1), 46 - 51.

    2002

    • Walker Z, Stevens T (2002). Dementia with Lewy bodies; clinical characteristics and diagnostic criteria. Journal of Geriatric Psychiatry and Neurology, 15(4), 188 - 194.
    • Harborne A, Walker Z, Clare L (2002). The role of Cognitive Measures in Predicting Decline in Functional Skills in Dementia: A Comparison of the MMSE and CAMCOG.
    • Strydom A, Hassiotis A, Walker Z (2002). Clinical use of structural magnetic resonance imaging in the diagnosis of dementia in adults with Down's syndrome. Irish Journal of Psychological Medicine, 19(2), 60 - 63.
    • Walker Z, Costa DC, Walker RWH, Shaw K, Gacinovic S, Stevens T, Livingston G, Ince P, McKeith IG, Katona CLE (2002). Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. Journal of Neurology, Neurosurgery and Psychiatry, 73(2), 134 - 140. doi:10.1136/jnnp.73.2.134
    • SantaCruz KS, Walker Z, Swagerty D, Piggott MA, Ryo-Yang M, McKeith IG, Raghavan R, Jaros E, Perry RH (2002). Clinical Presentations in Monozygotic Twins with Dementia with Lewy Bodies.. Journal of Geriatric Psychiatry and Neurology, 15(4), 188 - 194.
    • Stevens T, Livingston GA, Kitchen G, Manela M, Walker Z, Katona C (2002). Islington study of dementia subtypes in the community.. The British Journal of Psychiatry, 180(3), 270 - 276. doi:10.1192/bjp.180.3.270
    • Tabet N, Mantle D, Walker Z, Orrell M (2002). Endogenous antioxidant activities in relation to concurrent vitamins A,C. and E intake in dementia. International Psychogeriatrics, 14(1), 7 - 15. doi:10.1017/S1041610202008232

    2001

    • Hassiotis A, Walker Z (2001). Setting up a memory clinic. In Walker Z, Butler R (Ed.), The Memory Clinic Guide (pp. - ). : Martin Dunitz.
    • Tabet N, Mantle D, Walker Z, Orrell M (2001). Dietary and endogenous antioxidants in dementia. International Journal of Geriatric Psychiatry, 16(6), 639 - 641.
    • Walker Z (2001). Dementia with Lewy bodies. In (Ed.), Bridges into the future (pp. 365 - 376). : Meta Data, Berlin.
    • (2001). Current Medical Literature. Dementia Reviews, 4(1), - .
    • Walker Z (2001). The Memory Clinic.
    • (2001). Current Medical Literature. Dementia Reviews, 4(3), - .
    • Grace J, Daniel S, Stevens T, Shankar KK, Walker Z, Byrne EJ, Butler S, Wilkinson D, Woolford J, Waite J, McKeith IG (2001). Long-term use of rivastigmine in patients with dementia with Lewy bodies: An open-label trial. International Psychogeriatrics, 13(2), 199 - 205. doi:10.1017/S104161020100758X
    • Tabet N, Mantle D, Walker Z, Orrell M (2001). Vitamins, trace elements, and antioxidant status in dementia disorders. International Psychogeriatrics, 13(3), 265 - 275. doi:10.1017/S1041610201007669
    • Simmon P, Richardson B, Mullan E, Katona CLE, Walker Z, Orrell M (2001). Eligibility criteria for elderly mentally ill continuing care national Health Service patients: are they being met and do they need revision?. Age and Ageing, 30, 243 - 249.
    • (2001). Current Medical Literature. Dementia Reviews, 4(2), - .

    2000

    • McKeith IG, Grace JB, Walker Z, Byrne EJ, Wilkinson D, Stevens T, Perry EK (2000). Rivastigmine in the treatment of dementia with Lewy bodies: Preliminary findings from an open trial. International Journal of Geriatric Psychiatry, 15(5), 387 - 392.
    • Walker Z (2000). Neuroimaging in alzheimer's disease and other dementias. In Kelly C (Ed.), Alzheimer's Disease Handbook (pp. 67 - 77). : Merit Publishing International.
    • Walker Z (2000). The Challenge of Dementia with Lewy Bodies. Geriatric Medicine, 30(8), 23 - 25.
    • Walker Z, Allen RL, Shergill S, Mullan E, Katona CLE (2000). Three years survival in patients with a clinical diagnosis of dementia with Lewy bodies. International Journal of Geriatric Psychiatry, 15(3), 267 - 273.
    • Walker Z (2000). Assessment and Investigation of Dementia. In Kelly C (Ed.), Alzheimer's Disease Handbook (pp. 1 - 9). : Merit Publishing International.
    • (2000). Current Medical Literature. Dementia Reviews, 3(2), - .
    • (2000). Current medical Literature. Dementia Reviews, 3(1), - .
    • (2000). Current Medical Literature. Dementia Reviews, 3(3), - .
    • Walker Z (2000). Dementia with Lewy bodies. CPD Bulletin Old Age Psychiatry, 2(2), 40 - 41.
    • Walker Z (2000). Differential diagnosis of Alzheimer's disease. In Kelly C (Ed.), Alzheimer's Disease Handbook (pp. 17 - 23). : Merit Publishing International.
    • Rafalson L, Davis SP, Walker ZK, C LE (2000). Education Status and Letter Fluency in Alzheimer’s disease. Clinical Neuropsychological Assessment, 2, 103 - 112.

    1999

    • (1999). Current Medical Literature. Dementia Review, 2(3), - .
    • Costa DC, Walker Z, Serra-Mestre J, Gacinovic S, Lees A (1999). Potential clinical applications of FP-CIT: Experience from studies of 140 subjects.
    • Costa DC, Walker Z, Walker RWH, Gacinovic S, Livingstone G, Katona CLE (1999). Dementia with Lewy bodies: preliminary data on clinical, pathological and FP-CIT SPET correlations.
    • Walker Z, Costa DC, Ince P, McKeith IG, Katona CLE (1999). In-vivo demonstration of dopaminergic degeneration in dementia with Lewy bodies. LANCET, 354(9179), 646 - 647.
    • Richardson B, Walker Z, Katona CLE, Tannock C (1999). Cardiopulmonary resuscitation and other life supporting measures in elderly patients: attitudes of psychiatrists and geriatricians. Aging and Mental Health, 3(4), 336 - 339.
    • Costa DC, Walker Z, Gacinovic S, Serra-Mestre J, Walker RWH, Doder M, Livingstone G, O'Sullivan J, Lees A, Katona CLE (1999). Clinical applications of DaTSCAN TM and single photon emission tomography (SPET).
    • Walker Z, Grace J, Overshot R, Satarasinghe S, Swan A, Katona CL, McKeith IG (1999). Olanzapine in dementia with Lewy bodies: a clinical study.. Int J Geriatr Psychiatry, 14(6), 459 - 466.
    • (1999). Current Medical Literature. Dementia Reviews, 2(2), - .
    • Walker Z (1999). Book review: neuroimaging and the psychiatry of late life.

    1998

    • Walker Z, Walker RWH, Robertson MM, Stansfeld S (1998). Antidepressant treatment of chronic tension-type headache: a comparison between fluoxetine and desipramine. Headache, 38, 523 - 528.
    • Costa DC, Gacinovic S, Walker Z, Janssen AGM, Walker RWH, Serra-Mestre J, Katona CLE (1998). The integrity of pre-synaptic Dopamine transporter system may be studied with single detector gamma cameras using FP-CIT and SPET.
    • Allen R, Walker Z, Shergill SS, Katona CLE (1998). Attitudes to depression in hospital in-patients: a comparison of older and younger subjects. Aging and Mental Health, 2(1), 36 - 39.
    • Walker Z (1998). Depression in geriatric patients with physical illness. In Depression: Peer Selected Citations 1998.
    • Costa DC, Walker Z, Walker RWH, Gacinovic S, Janssen AGM, Katona CLE (1998). FP-CIT and SPET reveals severe Dopaminergic degeneration in dementia with Lewy bodies and drug-naive Parkinson's disease, compared with Alzheimer's disease and controls.
    • Butler RE, Costa DC, Walker Z, Katona CLE (1998). PET and SPET imaging in the dementias. In Murray IPC, Ell PJ (Ed.), Nuclear Medicine in Clinical Diagnosis and Treatment (pp. 713 - 728). : Churchill Livingstone.
    • Costa DC, Walker Z, Dizdarevic S, Ioannidis C, Gacinovic S, Walker RWH, Janssen AGM, Katona CLE (1998). Striatal binding index of FP-CIT: A simple method to separate Parkinson's disease patients and controls.
    • Shergill SS, Walker Z, Le Katona C (1998). A preliminary investigation of laterality in Parkinson's disease and susceptibility to psychosis. J NEUROL NEUROSUR PS, 65(4), 610 - 611.
    • Costa DC, Walker Z, Walker RWH, Gacinovic S, Janssen AGM, Katona CLE (1998). Dopamine transporter loss in dementia with Lewy bodies and Parkinson's disease compared with Alzheimer's disease and controls.

    1997

    • Walker Z (1997). Neuroimaging in dementia. Current Opinion in Psychiatry, 10, 309 - 313.
    • Walker Z, Allen R, Shergill SS, Katona CLE (1997). Neuropsychogical performance in Lewy body dementia and Alzheimer's disease. The British Journal of Psychiatry, 170, 156 - 158.
    • Allen R, Walker Z, Katona CLE (1997). Neuropsychological and imaging differences in dementia with Lewy bodies and Alzheimer's disease. The British Journal of Psychiatry, 171, 486 - 487.
    • Walker Z (1997). Old age, physical illness and depression. Current Medical Literature, 10(2), 35 - 42.
    • Walker Z (1997). Depression in geriatric patients with physical illness. Current Medical Literature, Psychiatry Reviews, 2(3), 5 - 10.
    • Costa DC, Walker Z, Gacinovic S, Janssen AGM, Walker RWH, Katona CLE (1997). In vivo demonstration of Dopamine transporter loss in dementia with Lewy bodies: an FP-CIT/SPET study.
    • Luttrell S, Watkin V, Livingston G, D'Ath P, Walker Z, Patel P, Shergill S, Dain A, Bielawska C, Katona C (1997). Screening for excessive alcohol consumption in older people. International Clinical Psychopharmacology, (12), 1151 - 1154.
    • Walker Z, Costa DC, Janssen AG, Walker RW, Livingstone G, Katona CL (1997). Dementia with lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon emission tomography.. Eur J Nucl Med, 24(6), 609 - 614.
    • Walker Z, Costa DC, D'ath PJ, Janssen AGM, Katona CLE (1997). Can SPET distinguish Lewy body dementia from Alzheimer's disease during life?. In DeDeyn PP, Dierckx RA, Alavi A, Pickut BA (Ed.), Neurology and Psychiatry (pp. 27 - 32). : John Libbey.
    • Walker Z, Costa DC, Janssen AG, Walker RWH, Livingston G, Katona CLE (1997). Dementia with Lewy bodies: A study of post-synpatic dopminergic recepters with iodine 123 iodobenzamide single-photon emission tomography. European Neuropsychopharmacology, 24, 609 - 614.
    • Walker Z, Katona CLE (1997). Depression in elderly people with physical illness. In Katona CLE, Robertson MM (Ed.), Depression and Physical Illness: A Practical Guide (pp. 169 - 181). : John Wiley & Sons.

    1996

    • Costa DC, Walker Z, Waddington W, Gacinovic S, Janssen AGM, Booij J, Van Royen EA, Katona CLE (1996). Pharmacokinetics and dosimetry of FP-CIT a new ligand to study the pre-synaptic transporter system.
    • Costa DC, Walker Z, Waddington W, Gacinovic S, Janssen AGM, Booij J, Van Royen EA, Katona CLE (1996). I-123-FP-CIT pharmacokinetics and dosimetry show great potential for the evaluation of dopamine transporter system in clinical routine.

    1995

    • Costa DC, Walker Z, Katona CLE (1995). Lewy body dementia- Dopamine D2 neuroreceptor availability studied with single photon emission tomography.
    • Allen RL, Walker Z, D'Ath PJ, Katona CLE (1995). Risperidone for psychotic and behavioural symptoms in Lewy body dementia. The Lancet, 346(8968), 185 - 185.
    • Walker Z, Katona CLE (1995). Depression in elderly people with physical illness:.
    • Walker Z, Costa DC, D'Ath PJ, Janssen AGM, Katona CLE (1995). Can SPET distinguish Lewy body dementia from Alzheimer's disease during life?.
    • Walker Z, Leek CA, D'Ath PJ, Katona CLE (1995). Psychiatric morbidity in elderly attenders of an Accident & Emergency department. International Journal of Geriatric Psychiatry, 10, 951 - 957.

    1994

    • Walker Z, Seifert R (1994). Violent Incidents in a Psychiatric Intensive Care Unit. British Journal of Psychiatry, 164, 826 - 828.
    • Walker Z, Seifert R (1994). Violent Incidents in a Psychiatric Intensive Care Unit.

    • Van Laere K, Varrone A, Booij J, Vander Borght T, Nobili F, Kapucu OL, Walker Z, Någren K, Tatsch K, Darcourt J (). EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2. European Journal of Nuclear Medicine and Molecular Imaging, , - .
    • Devine ME, Fonseca JAS, Walker Z (). Do cerebral white matter lesions influence the rate of progression from mild cognitive impairment to dementia?. International Psychogeriatrics, 25(01), 120 - 127. doi:10.1017/S1041610212000932
    • Walker RWH, Walker Z (). Dopamine transporter single photon emission computerised tomography in the diagnosis of dementia with Lewy bodies. Movements Disorders, , - .
    • Morgan S, Walker Z (). Efficacy of SPECT in differentiating DLB: A review of neurotransmitter and perfusion imaging. European Neurological Review, , - .
    • Booij J, Arbizu J, Darcourt J, Hesse S, Nobili F, Payoux P, Pappatà S, Tatsch K, Walker Z, Pagani M (). Appropriate use criteria for amyloid PET imaging cannot replace guidelines: On behalf of the European Association of Nuclear Medicine. European Journal of Nuclear Medicine and Molecular Imaging, 40(7), 1122 - 1125. doi:10.1007/s00259-013-2415-x